These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17574293)

  • 1. What difference does it make? The calculation of QALY gains from health profiles using patient and general population values.
    McNamee P
    Health Policy; 2007 Dec; 84(2-3):321-31. PubMed ID: 17574293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.
    Parkin D; Jacoby A; McNamee P; Miller P; Thomas S; Bates D
    J Neurol Neurosurg Psychiatry; 2000 Feb; 68(2):144-9. PubMed ID: 10644777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
    Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
    Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Difference Does It Make? A Comparison of Health State Preferences Elicited From the General Population and From People With Multiple Sclerosis.
    Goodwin E; Green C; Hawton A
    Value Health; 2020 Feb; 23(2):242-250. PubMed ID: 32113630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
    Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
    Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QALY weights for diabetic retinopathy--a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO.
    Heintz E; Wiréhn AB; Peebo BB; Rosenqvist U; Levin LÅ
    Value Health; 2012 May; 15(3):475-84. PubMed ID: 22583458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient versus general population health state valuations: a case study of non-specific low back pain.
    van Dongen JM; van denBerg B; Bekkering GE; van Tulder MW; Ostelo RWJG
    Qual Life Res; 2017 Jun; 26(6):1627-1633. PubMed ID: 28155048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of a QALY and VSI estimated with the chained approach.
    Olofsson S; Gerdtham UG; Hultkrantz L; Persson U
    Eur J Health Econ; 2019 Sep; 20(7):1063-1077. PubMed ID: 31172400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advocating a Paradigm Shift in Health-State Valuations: The Estimation of Time-Preference Corrected QALY Tariffs.
    Jonker MF; Donkers B; de Bekker-Grob EW; Stolk EA
    Value Health; 2018 Aug; 21(8):993-1001. PubMed ID: 30098678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to pay for a quality-adjusted life-year: the individual perspective.
    Bobinac A; Van Exel NJ; Rutten FF; Brouwer WB
    Value Health; 2010 Dec; 13(8):1046-55. PubMed ID: 20825620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life.
    Rowen D; Brazier J; Mukuria C; Keetharuth A; Risa Hole A; Tsuchiya A; Whyte S; Shackley P
    Med Decis Making; 2016 Feb; 36(2):210-22. PubMed ID: 26670663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unchained melody: revisiting the estimation of SF-6D values.
    Craig BM
    Eur J Health Econ; 2016 Sep; 17(7):865-73. PubMed ID: 26359242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method.
    Kharroubi SA; O'Hagan A; Brazier JE
    Stat Med; 2010 Jul; 29(15):1622-34. PubMed ID: 20209481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
    Olofsson S; Norrlid H; Persson U
    J Med Econ; 2016 Oct; 19(10):945-58. PubMed ID: 27149402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing and transforming PROMIS utility values to the EQ-5D.
    Hartman JD; Craig BM
    Qual Life Res; 2018 Mar; 27(3):725-733. PubMed ID: 29264776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.